SKYE BIOSCIENCE OTCMKTSSKYE STOCK QUOTE

https://skyebioscience.com/

LATEST NEWS FROM SKYE BIOSCIENCE

Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022

Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference

Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD

Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

Skye Bioscience Announces $7.0 Million Registered Direct Offering

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience Announces Special Virtual Investor Presentation

Skye Bioscience to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference

Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies

Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors

Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades

CEO Presenting on the Emerging Growth Conference on June 9. Register here

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

Skye Bioscience to Present at Upcoming Investment Conferences in April

Skye Bioscience to Present at Benzinga Biotech Small Cap Conference

Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

Skye Bioscience to Participate in Investment Conferences in February